# Anecortave Acetate Risk-Reduction Trial (AART)

> **NCT00307398** · PHASE3 · TERMINATED · sponsor: **Alcon Research** · enrollment: 2596 (actual)

## Conditions studied

- Dry AMD

## Interventions

- **DRUG:** Anecortave Acetate (AL-3789) sterile suspension, 15 mg or 30 mg
- **OTHER:** Anecortave Acetate Vehicle

## Key facts

- **NCT ID:** NCT00307398
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-03
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 2596 (ACTUAL)
- **Why stopped:** Management decision
- **Last updated:** 2012-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00307398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00307398, "Anecortave Acetate Risk-Reduction Trial (AART)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00307398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*